OBJECTIVE: To make evidence-based recommendations concerning the evaluation of the child with microcephaly. METHODS: Relevant literature was reviewed, abstracted, and classified. RECOMMENDATIONS were based on a 4-tiered scheme of evidence classification. RESULTS: Microcephaly is an important neurologic sign but there is nonuniformity in its definition and evaluation. Microcephaly may result from any insult that disturbs early brain growth and can be seen in association with hundreds of genetic syndromes. Annually, approximately 25,000 infants in the United States will be diagnosed with microcephaly (head circumference <-2 SD). Few data are available to inform evidence-based recommendations regarding diagnostic testing. The yield of neuroimaging ranges from 43% to 80%. Genetic etiologies have been reported in 15.5% to 53.3%. The prevalence of metabolic disorders is unknown but is estimated to be 1%. Children with severe microcephaly (head circumference <-3 SD) are more likely ( approximately 80%) to have imaging abnormalities and more severe developmental impairments than those with milder microcephaly (-2 to -3 SD; approximately 40%). Coexistent conditions include epilepsy ( approximately 40%), cerebral palsy ( approximately 20%), mental retardation ( approximately 50%), and ophthalmologic disorders ( approximately 20% to approximately 50%). RECOMMENDATIONS: Neuroimaging may be considered useful in identifying structural causes in the evaluation of the child with microcephaly (Level C). Targeted and specific genetic testing may be considered in the evaluation of the child with microcephaly who has clinical or imaging abnormalities that suggest a specific diagnosis or who shows no evidence of an acquired or environmental etiology (Level C). Screening for coexistent conditions such as cerebral palsy, epilepsy, and sensory deficits may also be considered (Level C). Further study is needed regarding the yield of diagnostic testing in children with microcephaly.
OBJECTIVE: To make evidence-based recommendations concerning the evaluation of the child with microcephaly. METHODS: Relevant literature was reviewed, abstracted, and classified. RECOMMENDATIONS were based on a 4-tiered scheme of evidence classification. RESULTS:Microcephaly is an important neurologic sign but there is nonuniformity in its definition and evaluation. Microcephaly may result from any insult that disturbs early brain growth and can be seen in association with hundreds of genetic syndromes. Annually, approximately 25,000 infants in the United States will be diagnosed with microcephaly (head circumference <-2 SD). Few data are available to inform evidence-based recommendations regarding diagnostic testing. The yield of neuroimaging ranges from 43% to 80%. Genetic etiologies have been reported in 15.5% to 53.3%. The prevalence of metabolic disorders is unknown but is estimated to be 1%. Children with severe microcephaly (head circumference <-3 SD) are more likely ( approximately 80%) to have imaging abnormalities and more severe developmental impairments than those with milder microcephaly (-2 to -3 SD; approximately 40%). Coexistent conditions include epilepsy ( approximately 40%), cerebral palsy ( approximately 20%), mental retardation ( approximately 50%), and ophthalmologic disorders ( approximately 20% to approximately 50%). RECOMMENDATIONS: Neuroimaging may be considered useful in identifying structural causes in the evaluation of the child with microcephaly (Level C). Targeted and specific genetic testing may be considered in the evaluation of the child with microcephaly who has clinical or imaging abnormalities that suggest a specific diagnosis or who shows no evidence of an acquired or environmental etiology (Level C). Screening for coexistent conditions such as cerebral palsy, epilepsy, and sensory deficits may also be considered (Level C). Further study is needed regarding the yield of diagnostic testing in children with microcephaly.
Authors: D A Custer; L G Vezina; D R Vaught; C Brasseux; C A Samango-Sprouse; M S Cohen; K N Rosenbaum Journal: J Dev Behav Pediatr Date: 2000-02 Impact factor: 2.225
Authors: N S den Hollander; M W Wessels; F J Los; N T Ursem; M F Niermeijer; J W Wladimiroff Journal: Ultrasound Obstet Gynecol Date: 2000-04 Impact factor: 7.299
Authors: W B Dobyns; E Andermann; F Andermann; D Czapansky-Beilman; F Dubeau; O Dulac; R Guerrini; B Hirsch; D H Ledbetter; N S Lee; J Motte; J M Pinard; R A Radtke; M E Ross; D Tampieri; C A Walsh; C L Truwit Journal: Neurology Date: 1996-08 Impact factor: 9.910
Authors: A J Barkovich; D M Ferriero; R M Barr; P Gressens; W B Dobyns; C L Truwit; P Evrard Journal: Neuropediatrics Date: 1998-06 Impact factor: 1.947
Authors: Andrew H Chon; Mary Rose Mamey; Sheree M Schrager; Douglas L Vanderbilt; Ramen H Chmait Journal: Prenat Diagn Date: 2018-01-24 Impact factor: 3.050
Authors: Ghayda M Mirzaa; Alex R Paciorkowski; Christopher D Smyser; Marcia C Willing; Anne C Lind; William B Dobyns Journal: Am J Med Genet A Date: 2011-08-03 Impact factor: 2.802
Authors: Nataliya Di Donato; Sara Chiari; Ghayda M Mirzaa; Kimberly Aldinger; Elena Parrini; Carissa Olds; A James Barkovich; Renzo Guerrini; William B Dobyns Journal: Am J Med Genet A Date: 2017-04-25 Impact factor: 2.802
Authors: Anne T Berg; Jason Coryell; Russell P Saneto; Zachary M Grinspan; John J Alexander; Mariana Kekis; Joseph E Sullivan; Elaine C Wirrell; Renée A Shellhaas; John R Mytinger; William D Gaillard; Eric H Kossoff; Ignacio Valencia; Kelly G Knupp; Courtney Wusthoff; Cynthia Keator; William B Dobyns; Nicole Ryan; Tobias Loddenkemper; Catherine J Chu; Edward J Novotny; Sookyong Koh Journal: JAMA Pediatr Date: 2017-09-01 Impact factor: 16.193
Authors: Janet D Cragan; Jennifer L Isenburg; Samantha E Parker; C J Alverson; Robert E Meyer; Erin B Stallings; Russell S Kirby; Philip J Lupo; Jennifer S Liu; Amanda Seagroves; Mary K Ethen; Sook Ja Cho; MaryAnn Evans; Rebecca F Liberman; Jane Fornoff; Marilyn L Browne; Rachel E Rutkowski; Amy E Nance; Marlene Anderka; Deborah J Fox; Amy Steele; Glenn Copeland; Paul A Romitti; Cara T Mai Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-11
Authors: Monica Zilmer; Andrew C Edmondson; Sumeet A Khetarpal; Viola Alesi; Maha S Zaki; Kevin Rostasy; Camilla G Madsen; Francesca R Lepri; Lorenzo Sinibaldi; Raffaella Cusmai; Antonio Novelli; Mahmoud Y Issa; Christina D Fenger; Rami Abou Jamra; Heiko Reutter; Silvana Briuglia; Emanuele Agolini; Lars Hansen; Ulla E Petäjä-Repo; John Hintze; Kimiyo M Raymond; Kristen Liedtke; Valentina Stanley; Damir Musaev; Joseph G Gleeson; Cecilia Vitali; W Timothy O'Brien; Elena Gardella; Guido Rubboli; Daniel J Rader; Katrine T Schjoldager; Rikke S Møller Journal: Brain Date: 2020-04-01 Impact factor: 13.501